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Oral Solubilized Ursodeoxycholic Acid Therapy in Amyotrophic 
Lateral Sclerosis: A Randomized Cross-Over Trial
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral solubilized 
formula in amyotrophic lateral sclerosis (ALS) patients, patients with probable or definite 
ALS were randomized to receive oral solubilized UDCA (3.5 g/140 mL/day) or placebo for  
3 months after a run-in period of 1 month and switched to receive the other treatment for 
3 months after a wash-out period of 1 month. The primary outcome was the rate of 
progression, assessed by the Appel ALS rating scale (AALSRS), and the secondary outcomes 
were the revised ALS functional rating scale (ALSFRS-R) and forced vital capacity (FVC). 
Fifty-three patients completed either the first or second period of study with only 16 of  
63 enrolled patients given both treatments sequentially. The slope of AALSRS was  
1.17 points/month lower while the patients were treated with UDCA than with placebo 
(95% CI for difference 0.08-2.26, P = 0.037), whereas the slopes of ALSFRS-R and FVC 
did not show significant differences between treatments. Gastrointestinal adverse events 
were more common with UDCA (P < 0.05). Oral solubilized UDCA seems to be tolerable in 
ALS patients, but we could not make firm conclusion regarding its efficacy, particularly 
due to the high attrition rate in this cross-over trial.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neu-
rodegenerative disease that primarily affects upper and lower 
motor neurons, resulting in death three to five years after symp-
tom onset in the majority of patients (1). The pathomechanism 
of ALS is largely unknown, but research efforts have been focused 
on several hypothetical models such as glutamate excitotoxicity, 
oxidative damage, mitochondrial dysfunction, inflammation 
and apoptosis (2). Numerous clinical trials have been performed, 
but unfortunately all failed to demonstrate any beneficial effects 
on the disease progression or survival, with the exception of rilu-
zole. 
  Ursodeoxycholic acid (3α, 7β-dihydroxy-5β-cholanic acid, 
UDCA), a hydrophilic tertiary bile acid, is a major component of 
black bear bile that was used in traditional Chinese medicine (3). 
It is the current mainstay of treatment of primary biliary cirrho-
sis as the only drug approved by the US FDA, and has been in-
creasingly used for the treatment of various cholestatic liver dis-
eases such as primary sclerosing cholangitis and progressive fa-
milial intrahepatic cholestasis (4, 5). Although the mechanisms 
of action is not completely understood, UDCA and its taurine-
conjugated derivative (TUDCA) have been shown to strongly 
inhibit apoptosis in different type of cells by either stabilizing 
the mitochondrial membrane, or modulating the expression of 
specific upstream targets of apoptosis (6-11). TUDCA improved 
the survival and function of nigral transplants in a rat model of 
Parkinson’s disease (12), and the neuroprotective effect was also 
reported in a transgenic mouse model of Huntington’s disease 
(13), and rat models of ischemic and hemorrhagic stroke (14, 15).
  ALS must be such a complex disease with numerous factors 
contributing to the degeneration of motor neurons, that an ap-
proach targeting a single molecule or process may not be effec-
tive (2). In this respect, UDCA may be a promising therapeutic 
candidate because of its multiple mechanisms of cytoprotective 
actions which may include antiapoptotic, immunomodulatory 
and antioxidant effects (6, 16, 17). Despite these therapeutic po-
tentials, however, clinical application of UDCA has been limited 
to the hepatobiliary disorders exclusively. This is because of its 
unique pharmacokinetic properties which prevent the molecule Min J-H, et al.  •  Oral Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis
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from being delivered through systemic circulation, for example, 
to the central nervous system at potentially therapeutic concen-
trations (18). UDCA capsules or tablets, for instance, contain acid 
crystals with a very low solubility at pH < 7, and after adminis-
tration of the pharmacological dose (10-15 mg/kg/day) UDCA 
is absorbed through passive non-ionic diffusion, which is large-
ly limited by dilution mostly in the small intestine (18). More-
over, a large proportion of UDCA taken up from the portal blood 
is conjugated with glycine or taurine during its first hepatic pas-
sage, and actively secreted into the bile (18).
  A new UDCA formula, oral solubilized UDCA (Yoo’s solution; 
US patent 6251428, 7166299, 7303768 with PTC), was developed 
to broaden its therapeutic targets beyond the liver and biliary 
tracts eluding those pharmacokinetic limitations such as the 
enterohepatic circulation and high first-pass metabolism. The 
new formula contains intact UDCA molecules and soluble starch 
conversion product that enables UDCA to remain in solution. 
The product is highly soluble in water with a solubility of 80 mg/ 
mL, and stable from pH 1 to 14 without producing precipitate 
(19, 20). It can deliver therapeutically effective amounts of solu-
bilized intact UDCA to the systemic circulation with a Cmax of 
20.4 μg/mL at a Tmax of 15 min in human blood after oral admin-
istration of single dose containing 500 mg of UDCA (20). More-
over, a preliminary study showed that UDCA can be effectively 
delivered to the central nervous system (cerebrospinal fluid, 
CSF) with oral administration of solubilized UDCA (described 
in the methods). The present study was performed to evaluate 
the efficacy and safety of oral solubilized UDCA treatment in 
patients with ALS. 
MATERIALS AND METHODS
Study design, patients and treatment
The study was a double-blind, placebo-controlled, randomized, 
cross-over, single center, phase III trial. Inclusion started in March 
2005, and the final patient completed the study in July 2007. Pa-
tients with definite or probable sporadic ALS, according the re-
vised El Escorial criteria, were enrolled (21). They had to be at 
or above 20 yr of age, and have disease duration of less than 60 
months. The Appel ALS rating scale (AALSRS) total score had to 
be between 40 and 120 at baseline (22). Patients who had a forced 
vital capacity of less than 30%, those with signs of major psychi-
atric disorders and/or dementia, and acute cholecystitis or oc-
clusion of bile duct, or patients who had another concomitant 
conditions likely to interfere with drug compliance and outcome 
assessment were excluded. Additional exclusion criteria were 
pregnancy and participation to other clinical trials. 
  Eligibility was assessed by two of the authors , and the eligible 
patients who gave informed consents were randomly assigned 
to one of the two treatment groups according to a randomiza-
tion schedule prepared by Prime Pharm Tech, Corp (Suwon, 
Korea). There was no stratification of patients according to the 
onset region, age or respiratory function, since all the patients 
enrolled were supposed to receive both treatments (oral solubi-
lized UDCA and placebo) sequentially in this cross-over trial. 
After a run-in period of 1 month, one group received oral solubi-
lized UDCA (UDCA 3.5 g/140 mL q.d., Prime Pharm Tech, Corp.) 
for 3 months, while the other group received placebo (identi-
cally-appearing, equal amount of solution q.d., Prime Pharm 
Tech, Corp.). Subsequently, the two groups switched to receive 
the other treatment for another 3 months during the second 
period of study. To eliminate a possible carry-over effect of oral 
solubilized UDCA, a wash-out period of 1 month was set at the 
beginning of the second period. To ensure blinding, placebo 
was made to be identical to oral solubilized UDCA in viscosity 
as well as appearance (color, packaging and labeling), and to be 
similar in bitter taste (by adding quinine hydrochloride in pla-
cebo).
  A preliminary study was performed to test if UDCA can be 
effectively delivered to the central nervous system with oral ad-
ministration of solubilized UDCA. Seven patients were all treated 
with oral solubilized UDCA with informed consents. After the 
first 3 months of treatment, pure UDCA was detected with con-
centrations ranging from 0.75 to 1.72 μM/L in CSF of these pa-
tients (JASCO Bile Acid Analysis System, Japan Spectroscopic 
Co., Ltd., Tokyo; data not shown). 
Efficacy and safety evaluation
Patients were scheduled to visit for outcome assessment at month 
1, 4, 5, and 8 throughout the 8-month study period. The prima-
ry outcome measure was the rate of progression, measured by 
the AALSRS, i.e., the slope of AALSRS (22, 23). Secondary out-
come measures were the deterioration rates, assessed by the 
revised ALS functional rating scale (ALSFRS-R) and forced vital 
capacity (FVC, % of predicted value) (24, 25). To preserve blind-
ing, efficacy measures were assessed by two independent inves-
tigators, who were not otherwise involved in the care of patients 
throughout the trial. Treatment adherence was checked monthly 
by a pharmacist, and noncompliant patients who took the study 
medications less than 80% of the given were considered to have 
violated the treatment protocol. Standard laboratory tests in-
cluding blood counts, chemistry, renal and liver function, and 
electrocardiogram were performed at baseline and at the post-
treatment discontinuation visit. Safety was evaluated as the in-
cidence and severity of adverse events, and their relationship to 
treatment which were based on the results of laboratory tests, 
patients’ reports and the investigator’s judgements. 
Statistical analysis 
We hypothesized that oral solubilized UDCA therapy slows the 
deterioration of function in patients with ALS, as assessed by 
comparing the slopes of AALSRS while the patients were treated Min J-H, et al.  •  Oral Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis
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with oral solubilized UDCA to those whilst on placebo. It was 
calculated that 48 patients, i.e., 24 patients in each treatment 
group, would have to be included in order to detect a difference 
of 10% in the mean slope of AALSRS between the two treatments 
with a power of 80% and an alpha risk of 5%. The sample size 
calculation was based on data from a previous study using the 
AALSRS to measure the functional deterioration in patients with 
ALS (26).
  Efficacy was analyzed using the data from the patients who 
completed the study without any protocol violation. No impu-
tation process was performed for missing data. Data for efficacy 
analysis were divided into two sets of per-protocol (PP). The first 
PP (PP) dataset were defined as the data from the patients who 
completed either the first or second period of study, while the 
second PP (PP’) dataset consisted of the data only from the pa-
tients who completed both the first and second periods of study. 
Data of the patients whose slopes of AALSRS were steep (defined 
as greater than 24 points during a 3-month period) were excluded 
from efficacy analysis because inclusion of those atypical pa-
tients who progressed very rapidly could seriously distort the 
result (26). Using the SAS General linear model (GLM), analysis 
of covariance (ANCOVA) was performed with the slope as the 
dependent variable, treatment as factor, and the period and se-
quence as covariates. Safety analysis was performed in all ran-
domized patients who had taken at least one study drug or pla-
cebo. Baseline characteristics of patients including demographic 
and clinical variables were compared between patients treated 
with oral solubilized UDCA and those with placebo. Incidence 
of adverse events was compared between the two treatments 
using the chi-square. Statistical significance was set at P < 0.05, 
and the results are reported with two-sided P values. 
Ethics statement
The study was conducted according to the Declaration of Hel-
sinki, and Korean Good Clinical Practice (KGCP) guidelines. The 
study protocol was submitted to and approved by the Korean 
Food and Drug Administration (KFDA) (16409), and the Insti-
tutional Review Board (IRB) of Seoul National University Hos-
pital (H-0301-099-007). All patients gave written informed con-
sent before trial entry. Overall trial-related activities and docu-
ments were overseen by an Independent Auditory Board (C&R 
Research, Seoul, Korea). 
RESULTS
The trial profile is illustrated in Fig. 1. A total of 80 patients were 
assessed for eligibility, and 64 patients were enrolled in this study 
(one in error). Reasons for exclusion were the AALSRS total score 
greater than 120 or disease duration longer than 60 months (n =  
10), severe depression (n = 3), and clinically possible ALS (n = 2) 
and cognitive impairment (n = 1). Forty of 63 patients were as-
signed to receive oral solubilized UDCA in the first period of 
study, and the other 23 patients to receive placebo. During the 
first period, 19 of 40 (47.5%) patients treated with oral solubilized 
6 analyzed 13 analyzed
4 lost to follow-up
4 discontinued d/t
adverse events
9 missed visits
4 progressed rapidly
‡
2 lost to follow-up
1 discontinued d/t
adverse events
5 missed visits
3 lost to follow-up
1 discontinued d/t
adverse events
8 missed visits
1 progressed rapidly
‡
2 lost to follow-up
1 discontinued d/t
adverse events
15 missed visits
16 excluded*
80 patients assessed for eligibility
40 received Oral UDCA 23 received placebo
64 Randomized
†
19 received Oral UDCA 31 received placebo
19 analyzed 15 analyzed
Fig. 1. Trial profile. *all not meeting inclu-
sion criteria; 
†one ineligible patient was 
randomized in error; 
‡excluded from anal-
ysis due to a rapid rate of progression, i.e., 
the Appel ALS total score change > 8 
points/month.Min J-H, et al.  •  Oral Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis
http://jkms.org   203 http://dx.doi.org/10.3346/jkms.2012.27.2.200
UDCA and 15 of 23 (65.2%) patients treated with placebo com-
pleted the study. All patients who completed the first period 
switched to receive the other treatment in the second period. 
The patients who dropped out during the first period of study 
were also scheduled to enter the second period of study after 
originally planned three months had passed with the other treat-
ment given for the second period. Thus, 31 of 40 (77.5%) random-
ized to oral solubilized UDCA and 19 of 23 (82.6%) randomized 
to placebo for the first period switched to receive placebo and 
oral solubilized UDCA, respectively, for the second period of 
study. During the second period, 6 of 19 (31.6%) treated with 
oral solubilized UDCA and 13 of 31 (41.9%) treated with place-
bo completed the study. Drop-out rates were higher during the 
second period (62%) than the first (46%), and also higher whilst 
on oral solubilized UDCA (57.6%) than placebo (48.1%). Only 
16 out of 63 enrolled patients completed the entire cross-over 
trial of 8-month, receving both treatments. Missed visits was the 
most common reason for drop-out (62%), followed by lost to fol-
low-up (18%), discontinuation due to adverse events (12%) and 
a rapid progression (8%). 
  The demographic and clinical characteristics of patients treat-
ed with either oral solubilized UDCA or placebo are outlined in 
Table 1. The patients treated with oral solubilized UDCA and 
placebo were comparable to each other at baseline with respect 
to sex, age at onset, disease duration from symptom onset to di-
agnosis, onset region, severity, and level of diagnostic certainty. 
We constructed the dataset for efficacy analysis separately for 
each outcome, because the AALSRS and FVC measures were 
missing more frequently than the ALSFRS-R. The results of effi-
cacy analysis for each outcome were summarized in Table 2. As 
for the PP datasets, the slope of AALSRS was 1.17 points/month 
lower while the patients were treated with oral solubilized UDCA 
than with placebo (2.3 vs 3.47 points/month, 95% CI for differ-
ence 0.08-2.26, P = 0.037). However, the slope of neither ALS-
FRS-R nor FVC (%) did not show any significant differences  
between treatments. Efficacy analysis from the PP’ datasets re-
vealed the same results as from the PP datasets. The slope of 
AALSRS was 1.63 points/month slower while the patients were 
treated with oral solubilized UDCA than with placebo (2.24 vs 
3.88 points/month, 95% CI for difference 0.60-2.68, P = 0.004), 
whereas the ALSFRS-R and FVC (%) deteriorated without signif-
icant differences between the two treatments. To infer the clini-
cal meaning from the slope data, Kaplan-Meier estimation was 
performed using a 20-points progression in the AALSRS total 
Table 1. Baseline characteristics of patients 
Parameters
Oral solubilized 
UDCA group 
(n = 25)
Placebo group   
(n = 28)
P value
Women 10 (40%) 8 (28.6%) NS
Age at onset (yr) 50.1 (2.2) 48.3 (1.7) NS
Time from symptom onset to 
   enrollment (month)
12.6 (1.8) 14.6 (4.3) NS
Onset region
   Bulbar
   Mixed
   Limb
 
  3
  3
19
 
  3
  2
23
NS
Appel ALS total score at baseline 69.3 (3.3) 70.4 (2.9) NS
ALSFRS-R at baseline 39.6 (0.8) 39.9 (0.7) NS
FVC (%) at baseline 72.9 (5.9) 69.4 (4.7) NS
Certainty of diagnosis
   Definite
   Probable 
 
  5
20
 
  8
20
NS
Data above are from the patients who completed either the first or second period of 
study. Baseline refers to the last measurement before the start of treatment during 
each period of study. ALSFRS-R and FVC (%) at baseline are from the first PP dataset 
on the corresponding outcome variable. Values are No. (%) or mean (standard error). 
UDCA, ursodeoxycholic acid; ALS, amyotrophic lateral sclerosis; ALSFRS-R, amyotrophic 
lateral sclerosis functional rating scale-revised; FVC, forced vital capacity.
Table 2. Results of efficacy analysis 
Variables Oral solubilized UDCA Placebo
LSM Difference (Placebo-Oral solubilized UDCA)
P value
Mean 95 % CI
PP datasets          
   Appel ALS total score 
      Adjusted slope 
n = 25
2.30 (0.41)
n = 28
3.47 (0.30) 1.17 0.08 to 2.26 0.037
   ALSFRS-R 
      Adjusted slope 
n = 48
-1.04 (0.28)
n = 44
-1.61 (0.28)
 
-0.57
 
-1.37 to 0.23
 
0.16
   FVC (%)
      Adjusted slope 
n = 17
-1.76 (1.03)
n = 16
-2.52 (1.02)
 
-0.76
 
-4.04 to 2.52
 
0.62
PP’ datasets    
   Appel ALS total score 
      Adjusted slope   
N = 16
2.24 (0.34)
 
3.88 (0.34)
 
1.63
 
0.60 to 2.68
 
0.004
   ALSFRS-R 
      Adjusted slope 
N = 35
-0.97 (0.32)
 
-1.54 (0.32)
 
-0.72
 
-1.64 to 0.2
 
0.22
   FVC (%)
      Adjusted slope 
N = 11
-0.76 (1.23)
 
-1.90 (1.23)
 
-1.13
 
-5.07 to 2.8
 
0.53
Least square means (LSM) of slope and p-values were obtained from the analysis of covariance model with change from baseline (slope) as the dependent variable, treatment 
(Oral solubilized UDCA vs placebo) as factor, and the period and sequence as covariates. Values in paresthesis are standard errors of LSM. Efficacy was analyzed separately for 
each outcome without imputation for missing data, and definitions of the PP and PP’ datasets were as followings: PP datasets, the data from the patients (n) who completed ei-
ther the first or second period of study; PP’ datasets, the data from the patients (N) who completed both the first and second periods of study. Min J-H, et al.  •  Oral Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis
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score as the end point which was reported to represent a clini-
cally meaningful lifestyle change. However, because of the short 
study period of this trial, the time to reach this endpoint had to 
be estimated in all patients, and was calculated by assuming that 
the slope of AALSRS would be linear from the start of treatment 
through the endpoint. As for the PP’ datasets, the time to a 20- 
points progression in the AALSRS total score was estimated to be 
delayed by 14.9 months in oral solubilized UDCA-treated group 
compared to placebo-treated group (22.5 vs 7.6 months, 95% CI 
for difference 2.97-26.8 months, P = 0.018) (Fig. 2). Additionally, 
we compared clinical features between 60 patients who dropped 
out and 53 patients who completed at least one part of the study. 
At baseline, sex, age at onset, age at enrollment, disease duration 
from symptom onset to diagnosis, onset region, severity, and 
level of diagnostic certainty were not significantly different be-
tween two groups (all, P > 0.05). Safety data from each period 
of study were pooled to provide a whole picture of the adverse 
event profile. The population for safety analysis consisted of 74 
patients who took oral solubilized UDCA, and 70 patients who 
took placebo (Table 3). Not included for safety analysis were the 
patien ts who did not take the study drug or placebo at all, 6 pa-
tients assigned to oral solubilized UDCA and 10 patients to pla-
cebo. 
  A total of 25 occasions of adverse events were reported in 17 
patients (23.0%) treated with oral solubilized UDCA, and 12 oc-
casions in 10 patients (14.3%) treated with placebo. Except for 
the expected complications of ALS such as dyspnea and dys-
phagia, adverse events that could be possibly attributed to the 
study drug or placebo were reported in 12 patients (16.2%, 16 
occasions) treated with oral solubilized UDCA, and in 6 patients 
(8.6%, 7 occasions) treated with placebo. Gastrointestinal adverse 
events were significantly more common in patients treated with 
oral solubilized UDCA (P < 0.05), but serious events were re-
ported in only one patient who discontinued the drug due to 
abdominal pain, anorexia and vomiting. None of the 80 patients 
who were randomized died during the 8-month period of study, 
with tracheostomy performed in 2 patients.
DISCUSSION
The results of this study suggest that oral solubilized UDCA ther-
apy may have a beneficial effect on the rate of functional decline 
in patients with ALS. As for the slope of AALSRS, the difference 
between oral solubilized UDCA and placebo was 1.17 and 1.63 
points per month on the average for the PP and PP’ datasets, re-
spectively, which correspond to 34% and 42% relative slowing 
of the rate of deterioration in this scale. Although estimated, the 
time to a 20-points progression in the AALSRS also showed that 
oral solubilized UDCA treatment could delay this endpoint by 
more than 1 yr compared to placebo. Although it was not statis-
tically significant, the efficacy data in the other outcomes also 
showed a trend favoring oral solubilized UDCA. Although gas-
trointestinal adverse events developed more frequently in pa-
tients treated with oral solubilized UDCA, these were mostly 
tolerable and oral high dose solubilized UDCA was well tolerated 
in vast majority of patients. Taken together, this study suggests a 
therapeutic potential and acceptable safety profile of oral solu-
bilized UDCA in ALS patients.
  However, no firm conclusion cannot be made on the efficacy 
of oral solubilized UDCA because of several critical problems 
and limitations of this study which should be acknowledged 
herein. First of all, the major problem was the large drop-out 
rate in this trial. In fact, only about a fourth of the initially ran-
Table 3. Incidence of adverse events 
Symptoms/signs
Placebo  
(n = 70)
Oral solubilized UDCA  
(n = 74)
Ophthalmic
   Cataract
  1
  1
  1
  1
Gastrointestinal*
   Abdominal pain
   Anorexia
   Dyphagia
   Diarrhea
   Dyspepsia
   Nausea
   Vomiting
  6
  0
  0
        1 (1)
  1
  2
  0
  2
18
       5 (1)
       2 (1)
  1
  5
  1
  1
       3 (1)
Neurological
   Dizziness
   Headache
  2
  1
  1
  2
  0
  2
Respiratory
   Dyspnea
  3
       3 (2)
  4
       4 (3)
Total* 12 25
Data are numbers of events (number of serious adverse events). *P < 0.05, chi-square 
test.
%
 
p
a
t
i
e
n
t
s
Months
Oral UDCA
Placebo
  10  20  30  40  50   60
100
80
60
40
20
0
Fig. 2. Kaplan-Meier survival curves, using a change of 20 points on the Appel ALS 
total score as the end point. Time to 20 points progression was estimated by assum-
ing a linearity of the change in the Appel ALS total score. In two patients whose slope 
was not above zero (zero in one, and -0.33 point/month in the other, both treated 
with oral solubilized UDCA), the time to 20 point progression was estimated to be 60 
months, i.e., 1 point/3 month.Min J-H, et al.  •  Oral Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis
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domized patients completed both parts of the study with missed 
visits, followed by lost to follow-up, being the most common 
drop-out reason. The patients, who had already severe disease 
at enrollment or became progressively more disabled during the 
study, tended to refuse to visit the clinic for outcome measures. 
These patients were also hard to keep contact with for consistent 
follow-up. Thus, it is likely that the broad inclusion criteria regard-
ing disease severity, and the lack of adherence to visit schedule 
for outcome measures account for the large attrition rate. The 
second problem of this study is the way data were analyzed, i.e., 
‘completers-only’ analysis. Since only the patients who com-
pleted the planned treatment course were included for efficacy 
analysis, this does not conform to the intention-to-principle. We 
cannot rule out faster declines for patients after their dropout, 
and excluded cases can cause a bias, although baseline clinical 
features of patients completing the study and patients dropping-
out the study were not different. However, we could not apply 
the intention-to-treat principle, since the attrition rate was too 
large for us to perform any valid imputation procedure for miss-
ing data. Other limitations of this study are the short treatment 
period and limited number of datapoints to assess the rates of 
functional deterioration. Treatment period of 3 months might 
not be sufficient duration to capture a small effect. In addition, 
the outcome measures may not be reproducible to give accu-
rate statistics with only two datapoints. Finally, it also should be 
pointed out that all the patients who were excluded due to their 
rapid progression rates (> 8 points/month) were those taking 
oral solubilized UDCA. 
  An ethical concern about treatment with placebo was the main 
reason we adopted a cross-over design instead of conventional 
two parallel arm study (27). It was also expected that the cross-
over design would be more efficient in detecting the same effect 
with a smaller sample size, since within-patient variability may 
be smaller than between-patient variability when the deteriora-
tion rates of functional scales are used as endpoints (28, 29). 
However, there might be disadvantages to the cross-over trial as 
well, and some of these indeed caused difficulties for analysis 
and interpretation of our study. First, there may be a bias which 
is related to the unequal randomization for the first treatment 
period. It is likely that merely the sequence of treatment may 
explain the difference between treatments, although we adjust-
ed the effects of sequence and period using ANCOVA to evalu-
ate the effect of treatment itself. The other problem is a treatment-
period interaction, so-called a carry-over effect. The wash-out 
period of 1 month may be insufficient to completely eliminate 
the effect of treatment given before. However, we could exclude 
the inflation of alpha-error resulting from the carry-over effect, 
because any persistence of the drug effect would have reduced 
the magnitude of difference during the second treatment period.
  It is worth emphasizing that UDCA can be effectively deliv-
ered to the central nervous system (CSF) with oral administra-
tion of solubilized UDCA in our study. A recent pilot study by 
Parry et al. also showed that UDCA was well absorbed after oral 
administration and crossed the blood-brain barrier in a dose-
dependent manner in ALS patients (30). Eighteen patients were 
received UDCA in tablet formula at doses of 15, 30, and 50 mg/
kg of body weight per day and the concentration of UDCA in 
CSF ranged 43.1 to 281.7 nM/L after 4 weeks of treatment. These 
results suggest that oral UDCA is well delivered to CSF of ALS 
patients and the therapeutic effects deserve to be expected al-
though it remains to be elucidated which formula or dose of 
UDCA is more tolerated, absorbed, delivered and effective in 
ALS patients. 
  Although the mechanisms of cytoprotection of UDCA remain 
to be elusive, it does not seem to be limited to hepatic cells. UDCA 
modulates the apoptotic threshold in both hepatic and non-he-
patic cells through the downregulation of p53 pathway (10, 11). 
Recently, a study using oral solubilized UDCA demonstrated 
that UDCA treatment can suppress cisplatin-induced p53 accu-
mulation and apoptosis in mouse sensory neurons (19). It was 
also reported that this highly soluble and acid stable UDCA for-
mula can scavenge the reactive oxygen species and prevent apop-
tosis in Helicobacter pylori-induced gastritis (20). In line with 
these previous reports, we also found that the new UDCA for-
mula improved the motor performance and survival of G93A 
SOD1 mutant transgenic mice (in preparation). Therefore, the 
therapeutic effect of UDCA may be ascribed to the successful 
delivery of UDCA to the central nervous system and its multiple 
cytoprotective actions. 
  Oral solubilized UDCA treatment seems to be tolerable in ALS 
patients, but regarding the efficacy we could not make any con-
clusions due to several problems and limitations of this pilot 
study as discussed above. Still, the effect of UDCA deserves to 
be expected in ALS, due to its multiple neuroprotective mecha-
nism. As we know, a phase II trial for the efficacy and tolerabili-
ty of tauroursodeoxycholic acid, taurine conjugate of UDCA in 
ALS patients is also ongoing (NCT00877604) by Italian research-
ers. Further large scale study with minimal attrition rate is war-
ranted to confirm the efficacy and safety of oral solubilized UDCA 
for patients with ALS. 
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